SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001178913-20-001138
Filing Date
2020-04-20
Accepted
2020-04-20 13:14:34
Documents
4
Group Members
ALON LAZARUSARKIN BIO VENTURE PARTNERS, LTD.ARKIN BIO VENTURES LIMITED PARTNERSHIP

Document Format Files

Seq Description Document Type Size
1 SC 13D zk2024286.htm SC 13D 160759
2 EXHIBIT 1 exhibit_1.htm EX-99 6969
3 EXHIBIT 3 exhibit_3.htm EX-99 51665
4 EXHIBIT 4 exhibit_4.htm EX-99 3337
  Complete submission text file 0001178913-20-001138.txt   224169
Mailing Address 6 HACHOSHLIM ST. HERZELIA L3 4672406
Business Address
Arkin Moshe (Filed by) CIK: 0001321178 (see all company filings)

Type: SC 13D

Mailing Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421
Business Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421 617-513-8774
Keros Therapeutics, Inc. (Subject) CIK: 0001664710 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-91484 | Film No.: 20802082
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences